

1 **Affect and post-COVID-19 symptoms in daily life: An exploratory**
2 **experience sampling study**

3 Gerko Schaap^{1*}, Marleen Wensink¹, Carine J. M. Doggen^{2,3}, Job van der Palen^{4,5}, Harald E.
4 Vonkeman^{1,6}, and Christina Bode¹

5

6 ¹ Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands

7 ² Department of Health Technology and Services Research, Technical Medical Centre, University of
8 Twente, Enschede, The Netherlands

9 ³ Clinical Research Centre, Rijnstate Hospital, Arnhem, The Netherlands

10 ⁴ Department of Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands

11 ⁵ Section of Cognition, Data and Education, University of Twente, Enschede, The Netherlands

12 ⁶ Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, The
13 Netherlands

14

15 *Corresponding author

16 E-mail: g.schaap@utwente.nl (GS)

17

Affect and Post-COVID-19 Symptoms in Daily Life

18 **Abstract**

19 Insight into the daily life experiences of patients with post-COVID-19 syndrome is lacking. The
20 current study explored temporal fluctuations of and associations between positive and negative affect
21 and symptoms throughout the day in previously hospitalised post-COVID-19 patients using an
22 experience sampling methodology. Ten participants (age: median = 60, interquartile range = 9 years;
23 50% women ; 80% ≥ 1 comorbidity; 8–12 months since hospital discharge) filled out brief online
24 questionnaires, six times a day for 14 consecutive days. Positive and negative affect, and self-reported
25 symptoms (physical and mental fatigue, cognitive functioning, dyspnoea, and pain) were assessed in
26 real-time. Primarily, graphs were analysed to assess the individual longitudinal courses of and
27 (concurrent and time-lagged) associations between affect and symptoms. Secondly, correlations or
28 multilevel linear regression models were used to support these interpretations. Visual assessment
29 showed limited temporal fluctuation in affect and symptoms. All symptoms appeared to associate
30 positively with each other (correlations between .26 and .85). Positive affect was associated with lower
31 symptoms severity (β 's between -.28 and -.67), and negative affect with higher symptoms severity (β 's
32 between .24 and .66). Time-lagged analyses showed that – adjusted for residual symptom severity of
33 prior measurements – both types of affect predicted symptom severity two hours later (β 's between -.09
34 and -.31 for positive affect; between .09 and .28 for negative affect). These findings suggest that positive
35 and negative affect may play important roles in post-COVID-19 symptom experience and temporal
36 fluctuation.

37

38 **Keywords:** Post-COVID-19 syndrome; long COVID; symptoms; affect; Experience Sampling
39 Methodology; Ecological Momentary Assessment

40 Introduction

41 While most people recover from a SARS-CoV-2 infection, a substantial group struggles with
42 persistent symptoms. These sequelae are often referred to as long-COVID or as post-COVID-19
43 syndrome, which can be defined as “signs and symptoms that developed during or after an infection
44 consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative
45 diagnosis” [1]. Estimated prevalence ranges between 6 to 45 percent of COVID-19 survivors [2-4],
46 depending on definitions, populations, vaccination status, and SARS-CoV-2 variants within these
47 samples. Most frequently reported post-COVID-19 symptoms include fatigue, cognitive dysfunction or
48 brain fog, respiratory problems such as dyspnoea (breathlessness), chronic pain, and loss of sense of
49 smell; often co-occurring [3, 5-9]. Previous research is mostly limited to cross-sectional or cohort
50 studies, and few studies looked into the severity of these symptoms, their daily fluctuations, and the
51 interrelations between these symptoms. Similarly, while reviews [6, 8] and qualitative studies [10-13]
52 reported the effects on mental health and health-related quality of life, the daily fluctuations over time
53 of positive and negative affect in post-COVID-19 patients have not yet been investigated.

54 Affect may play an important role in the severity, daily course, and potentially management of
55 post-COVID-19 symptoms. One relevant framework to understand the associations between affect and
56 symptoms is the Broaden-and-Build theory of positive emotions [14, 15]. Negative emotions narrow
57 patients’ attention and behaviours towards specific action tendencies necessary for survival, such as fear
58 evoking an urge to escape [16]. In contrast, positive emotions can broaden patients’ perspectives and
59 approaches and help build personal physical, cognitive, social and psychological resources [14]. For
60 health, this translates into the risk for negative affect to restrict one’s attention on symptoms, whereas
61 positive affect may help patients to find additional resources to cope with their symptoms and aid with
62 self-management in general. This relationship between affect and symptoms has been found in many
63 patient populations, and the directions of these relationships can be surprising; while it seems common
64 sense that negative affect follows from increased symptom severity, the reverse can also be true. Both
65 negative and positive affect have been found to be bidirectionally associated with or predictive of
66 chronic symptoms such as fatigue, dyspnoea, and pain in various patient populations [17-22]. These

Affect and Post-COVID-19 Symptoms in Daily Life

67 studies mostly made use of cross-sectional designs and investigated these relations at a trait level or
68 relatively stable level, and hence provide little insight into short-term associations. In addition,
69 investigating whether affect informs an increase or decrease of symptom severity shortly later allows
70 for a richer, more detailed and nuanced understanding of illness experiences on a daily level. Moreover,
71 this understanding may guide in identifying opportunities for more advanced interventions; advanced in
72 the sense of potential for tailoring and personalisation. Currently it is not known whether positive and
73 negative affect are predictive of post-COVID-19 symptoms, and how these are experienced real-time
74 over the day.

75 To address the gaps in current knowledge, this observational study aimed to explore the daily
76 courses of and interrelations between positive and negative affect and post-COVID-19 symptom
77 severity, such as of fatigue, cognitive dysfunction, dyspnoea, and pain. An Experience Sampling
78 Methodology (ESM) has been applied, which allowed investigating these aspects in daily life through
79 repeated real-time assessments. Moreover, this method helps overcome recall bias, and due to the
80 repeated observations within participants, allows for rich and robust insights in patients' daily
81 experiences, even in small patient samples [23]. The following research questions were to assess: (1)
82 temporal fluctuations of affect and post-COVID-19 symptoms; (2) whether these symptoms were
83 associated with (a) positive and (b) negative affect measured concurrently; and (3) whether symptoms
84 were predicted by (a) positive and (b) negative affect measured at an earlier timepoint using time-lagged
85 analyses.

86

87 **Methods**

88 **Recruitment**

89 This study is part of a larger, on-going cohort study on the long-term impact of severe COVID-
90 19 requiring hospitalisation (registered at ClinicalTrials.gov; NCT05813574). For the present study,
91 participants were selected based on self-reported health status three months after hospital discharge and
92 their self-assessed health status at the time of recruitment. Formerly hospitalised COVID-19 patients
93 who indicated their health to be much worse compared to a year ago on the Dutch Short Form Health

Affect and Post-COVID-19 Symptoms in Daily Life

94 Survey (SF-36)[24] were selected for an interview [13]. During the interview, approximately 9 months
95 after hospital discharge, self-perceived health status was reassessed, and participants were screened for
96 symptoms (e.g. fatigue). If participants still suffered from post-COVID-19-associated symptoms, they
97 were invited for the present study. Out of the 16 selected candidates, 11 were willing to participate.

98 Inclusion criteria were: a) having been discharged from hospital after polymerase chain reaction-
99 confirmed acute COVID-19; b) persisting, fluctuating symptoms attributed by the participant to post-
100 COVID-19 syndrome; c) ≥ 18 years of age; d) proficiency in Dutch; and e) willingness to install a
101 smartphone-based measurement app. Participants were excluded from analysis in case of compliance
102 rates $< 30\%$ of the daily assessments [23]. All participants provided written informed consent, and the
103 Medisch Spectrum Twente Institutional Review Board (K20-30) and the Ethics Committee Behavioural,
104 Management and Social Sciences of the University of Twente, the Netherlands (210799) approved the
105 study.

106

107 **Procedure and measurements**

108 Using an ESM setup, this study set out to examine daily fluctuations of and associations between
109 affect and post-COVID-19 symptom severity. Data were collected between September 5 and October
110 27, 2021, using the Ethica platform (ethicadata.com) and the related Ethica smartphone application.
111 ESM data consisted of daily questionnaires on symptoms, feelings, and behaviours. Additional data
112 were collected, but were beyond the scope of this study and are discussed elsewhere [25]. See Appendix
113 S1 for the complete questionnaires in Dutch (original) and English (translated). Demographic and
114 health-related characteristics were retrieved from hospital medical records with participants' approval.

115 Participants were followed for 14 consecutive days via seven daily self-report questionnaires
116 prompted by a beep signal, of which six were relevant for this study. These short questionnaires – taking
117 approximately two minutes – were prompted semi-randomly within two-hour intervals at 08.00 – 09.59,
118 10.00 – 11.59, 12.00 – 13.59, 14.00 – 15.59, 16.00 – 17.59, and 18.00 – 19.59 (i.e. signal-contingent
119 sampling). Each notification expired after 15 minutes to prevent reactivity (i.e. participants 'preparing
120 themselves' for the prompts) without being too inconvenient [23, 26].

Affect and Post-COVID-19 Symptoms in Daily Life

121 The questionnaires assessed, in fixed order, symptom severity and affect. Fatigue – assessed as
122 physical fatigue and mental fatigue – and dyspnoea were observed real-time using statements (“right
123 now, I feel shortness of breath”) that could be answered using 7-point Likert-type answers: 1 – ‘strongly
124 disagree’ to 7 – ‘strongly agree’. Cognitive function was assessed by asking for clarity of thought (“how
125 is your ‘thinking’ (concentration, memory, attention) right now?”) on a visual analogue scale (VAS): 0
126 – ‘slow and difficult’ to 10 – ‘sharp and alert’. This scale was reversed for analysis (cognitive
127 dysfunction), so that higher scores indicated higher severity. Pain was assessed first by asking if the
128 participant experienced pain ‘right now’ (presence of pain). If affirmative, four additional prompts
129 opened up to assess the severity of headache, joint pain, chest pain, and pain ‘elsewhere in the body’ or
130 non-specific, which could be answered on four VAS: 0 – ‘no pain’ to 10 – ‘worst imaginable pain’.
131 However, as these pains varied too much between participants, the VAS were omitted from further
132 analysis. Nevertheless, their pain courses over time per participant were visualised and are reported in
133 Appendix S4. Affect was assessed using statements on five negative (anxious, gloomy, sad, irritable,
134 and disappointed) and five positive feelings (excited, relaxed, satisfied, thankful, and joyful; e.g. “right
135 now, I feel satisfied”), to be answered on a 7-point Likert-type scale: 1 – ‘strongly disagree’ to 7 –
136 ‘strongly agree’. Two mean scales of the five positive affect items and five negative affect items were
137 created as intercorrelations within these constructs were very high (both: Cronbach’s $\alpha = .96$).
138 Additionally, a categorical variable (affect category) was made to indicate whether participants were
139 predominantly positive (positive affect >4), predominantly negative (negative affect >4) or neither
140 predominantly positive nor negative (‘neutral’). All items were based on previously validated
141 questionnaires or ESM studies [27-34].

142

143 **Data analysis**

144 ESM data consisted of observations (level 1) within days (level 2) within individuals (level 3).
145 To make full use of the richness of these observations, data were primarily assessed visually.
146 Observations were plotted for exploration per participant (affect and symptoms), per symptom by affect

Affect and Post-COVID-19 Symptoms in Daily Life

147 category, and per symptom at the current time (t) with affect category of the previous time point (lagged
148 t-1). The graphs were plotted in RStudio version 23.03.0 +386 [35].

149 Additionally, statistical models were used to support these interpretations. Statistical evidence
150 for associations between symptoms were explored using personal averages (Person Mean) of each
151 participant to account for potential within-person fluctuations. Spearman rank correlations (r_s) were used
152 to account for non-parametric distributions and the small sample size. To assess potential associations
153 between affect and symptoms structured as two levels (observations nested within participants),
154 multilevel linear regression (MLR) models via the SPSS MIXED procedure were used. These models
155 also account for randomly missing observations, which is common in ESM studies. The models
156 accounted for participants (*subjects*) and timepoints (*repeated measures*), and were set up with restricted
157 maximum likelihood estimations and first-order autoregressive (AR1) covariance structure, which was
158 found to be best fitting according to the Akaike Information Criterion (AIC). As variables were
159 measured with different scales, Z-scores were used for analysis and to retrieve standardised regression
160 estimates. In the concurrent MLR models, each symptom was the outcome variable with either positive
161 affect or negative affect as the fixed covariate. Due to a strong correlation between positive affect and
162 negative affect ($r_s = -.82$), these variables were examined separately in univariate MLR. To examine the
163 prospective associations, positive and negative affect were lagged to the previous timepoint (t-1) in
164 relation to the timepoint of the symptom. For these models, each first symptom measurement of the day
165 was omitted, as the time between prior affect and symptom was too long (e.g. affect at T6 (e.g. 18.30)
166 was adjusted to not predict an effect on fatigue next day at T7 (08.30)). Additionally, the outcome
167 symptom was lagged t-1 and added as fixed covariate, to adjust for a continuance or residual experience
168 of the symptom. Statistical significance was assessed using 95% confidence intervals and $\alpha < .05$.
169 Standardised regression estimates were interpreted as small ($>.1$), medium ($>.3$) or large ($>.5$) effect
170 size following Cohen's guidelines [36]. Descriptive statistics are presented in absolute number and
171 percentages or median (*Mdn*) and interquartile range (*IQR*). IBM SPSS Statistics 28 was used for all
172 statistical analyses.

173

174 **Results**

175 **Sample characteristics**

176 After removing one participant with a compliance rate <30%, the final sample comprised 10
177 participants, who were between 48 and 76 (*Mdn* = 60, *IQR* = 9) years old and half of whom were women
178 (*n* = 5). Five participants had one comorbidity, three participants had two or more and two had no
179 comorbidities. All but two participants (80%) were overweight (Body Mass Index ≥ 25 ; *Mdn* = 29.0,
180 *IQR* = 14.6, *Min* = 22.0, *Max* = 41.8). Observations were made between 8 and 12 (*Mdn* = 10, *IQR* = 2)
181 months after hospital discharge. Compliance rates of participants varied between 32 and 92% (*Mdn* =
182 63.5%, *IQR* = 40.1%), with in total 502 completed questionnaires.

183

184 **Courses of post-COVID symptoms and affect**

185 Visual assessment of the daily average symptom severity per participant (Fig 1) suggested that
186 there were clear between-person differences in experiences of symptoms. Furthermore, physical and
187 mental fatigue, dyspnoea and, to a lesser extent, cognitive dysfunction associated with each other over
188 time on a daily level: an increase in one symptom co-occurred with an increase in the other. This
189 interpretation was supported by correlational analyses of person mean severities (r_s between .37 and .85,
190 $p < .001$; Table 1). For example, if a participant tends to experience physical fatigue, they also tend to
191 experience cognitive dysfunction ($r_s(8) = .80$, $p < .001$). Although less obvious from the visual
192 assessment, presence of pain likewise was weakly to moderately correlated to higher severity of other
193 symptoms (r_s between .26 and .54, $p < .001$; Table 1). Visual assessment of the graphs (see Fig 2 for the
194 course of physical fatigue per participant; see S2 for courses of mental fatigue, cognitive dysfunction,
195 dyspnoea and pain per participant) revealed that symptoms fluctuated over time to various degrees.
196 Cognitive dysfunction and pain showed the least variability and were mostly stable within participants.
197 Aside from that, no clear temporal patterns were observed within participants. To illustrate, while
198 physical fatigue often was lower in the afternoon for participant B, this was not necessarily the case
199 every day (Fig 2).

Affect and Post-COVID-19 Symptoms in Daily Life

200 **Fig 1. Daily average symptom severity over 14 days for participants A – J.** Pain presence was a
 201 dichotomous variable, with 1 = present and 0 = absent. Consequently, scores of e.g. 0.8 indicate that a
 202 participant did mostly but not always experience pain that day. See Fig 2 and Appendix S2 for more
 203 detailed insights in symptom courses.

204 **Fig 2. Course of physical fatigue over 14 days with corresponding affect per participant A – J.**

205

206 **Table 1. Spearman correlations between symptoms at person mean level.**

	Physical fatigue	Mental fatigue	Cognitive dysfunction	Dyspnoea
Physical fatigue	-			
Mental fatigue	.76***	-		
Cognitive dysfunction	.73***	.37***	-	
Dyspnoea	.88***	.53***	.66***	-
Pain presence	.25***	.32***	.27***	.37***

207 *** = $p < .001$.

208

209 Affect was mostly stable within participants, with two participants (C and I, Fig 2; see S4 for
 210 courses of and interrelations between positive and negative affect per participant) predominantly
 211 experiencing negative affect. No evidence for emotional instability was found (S4).

212

213 **Associations between affect and post-COVID symptoms**

214 **Concurrent associations**

215 Overall, negative affect co-occurred with higher severity in all symptoms (Fig 2 and S2).
 216 Additionally, experiencing neither predominantly positive nor negative ('neutral') affect co-occurred
 217 with higher symptom severity. Conversely, predominantly positive affect co-occurred more often with

Affect and Post-COVID-19 Symptoms in Daily Life

218 lower symptom severity. Pain seemed to be present regardless of affective tendencies in most
219 participants. MLR models (Table 2) supported these assessments for all associations, and seem to
220 suggest that both affects influence symptoms to a similar extent. For example, cognitive dysfunction
221 was (almost) strongly and significantly associated negatively with positive affect ($\beta = -.46$) and
222 positively with negative affect ($\beta = .51$).

223

224 **Table 2. Overview of 10 univariate models of positive and negative affect as concurrent predictors**
225 **of symptoms.**

Outcome	Positive affect			Negative affect		
	β	SE	95%CI	β	SE	95%CI
Physical fatigue	-.67	0.04	-.75 to -.59	.59	0.05	.49 to .69
Mental fatigue	-.59	0.05	-.69 to -.49	.66	0.05	.56 to .76
Cognitive dysfunction	-.46	0.05	-.55 to -.36	.51	0.06	.39 to .62
Dyspnoea	-.49	0.05	-.60 to -.39	.37	0.07	.24 to .50
Pain presence	-.28	0.06	-.39 to -.16	.24	0.07	.10 to .38

226 Standardised estimates of fixed covariate (either positive or negative affect) on outcome (symptom) in
227 univariate multilevel linear regression models. All associations were statistically significant, $p < .001$.
228 SE = standard error; 95%CI = 95% confidence intervals presented with respectively lower and upper
229 limits.

230

231 **Time-lagged associations**

232 To explore whether symptoms were influenced by affect, positive and negative affect were
233 lagged to the prior observation (t-1; visualisations in S3). As affect was relatively stable within
234 participants, influences are inconclusive, but a change from positive to 'neutral' or negative affect might
235 indicate a worsening of symptom severity (see e.g. Participant A). MLR models showed that although
236 symptom severity often was a continuance or remnant of previous measurement – especially for the
237 more stable symptoms such as cognitive dysfunction and presence of pain – both positive and negative

Affect and Post-COVID-19 Symptoms in Daily Life

238 affect still were significant but mostly weak predictors (Table 3), suggesting a small influence of affect
 239 on symptoms two hours later. Post-hoc analyses showed that, in line with the stable affect trajectories,
 240 time-lagged symptoms were not significant predictors of positive and negative affect two hours later.

241

242 **Table 3. Overview of 10 multivariate models of positive and negative affect as time-lagged**
 243 **predictors of symptoms.**

Outcome	Predictor	Positive affect			Negative affect		
		β	SE	95%CI	β	SE	95%CI
Physical fatigue	Affect t-1	-.31	0.05	-.41 to -.20	.27	0.05	.17 to .36
	Physical fatigue t-1	.46	0.05	.36 to .57	.51	0.05	.41 to .60
Mental fatigue	Affect t-1	-.18	0.05	-.27 to -.08	.28	0.05	.19 to .38
	Mental fatigue t-1	.65	0.05	.56 to .74	.54	0.05	.45 to .64
Cognitive dysfunction	Affect t-1	-.14	0.04	-.21 to -.07	.12	0.03	.06 to .19
	Cognitive dysfunction t-1	.82	0.04	.75 to .89	.85	0.03	.78 to .91
Dyspnoea	Affect t-1	-.22	0.04	-.31 to -.14	.18	0.04	.10 to .26
	Shortness of t-1	.61	0.05	.52 to .71	.67	0.04	.58 to .75
Pain presence	Affect t-1	-.09 [†]	0.03	-.15 to -.03	.09 [†]	0.03	.03 to .15
	Pain t-1	.82	0.03	.76 to .89	.83	0.03	.76 to .90

244 Standardised estimates of fixed covariates (residual symptom and (either positive or negative) affect)
 245 on outcome (symptom) in multivariate multilevel linear regression models. The first preceding
 246 measurement of each predictor is represented as t-1. All associations were statistically significant at p
 247 $<.001$, except for [†]: $p = .006$. SE = standard error; 95%CI = 95% confidence intervals presented with
 248 respectively lower and upper limits.

249 **Discussion**

250 This study explored the daily courses of and interrelations between affect and post-COVID-19
251 symptoms using an ESM approach. The main finding was that both positive and negative affect
252 predicted symptom severity both concurrently and two hours later. Moreover, post-COVID-19
253 symptoms were found to fluctuate in severity both within and between days, and these severities
254 fluctuated in co-occurrence with each other.

255 This study showed that affect might play a role in the experience of post-COVID-19 symptom
256 severity. This finding is in line with expectations that symptom severity is reduced in occurrence with
257 and after positive affect, which is based on the Broaden-and-Build framework [14]. Moreover, the
258 results are in accordance with previous findings on the relationships between trait affect and fatigue,
259 dyspnoea and pain in other patient populations [17, 20, 21, 37]. Furthermore, they are comparable to
260 findings in functional somatic syndromes such as fibromyalgia and chronic fatigue syndrome. For these
261 syndromes, it has been reported that negative affective states and negative trait affect elicit increased
262 symptom severity [22, 38], and that positive trait affect was associated with decreased symptom severity
263 [22]. The present study suggests that similar affect – symptom relationships also exist in post-COVID-
264 19 patients, and adds to the understanding that these relationships occur on a momentary level and have
265 short-term persisting effects by showing that small to medium effects of positive and negative affect on
266 symptoms can also be observed two hours later.

267 Based on visual assessment, a difference in the relationship of positive and negative affect with
268 symptom severity was observed. Negative affect was mostly consistent within two participants, while
269 positive affect fluctuated more often and co-occurred with fluctuating symptom severity. This might
270 suggest that there are important between- and within-individual differences. Previous findings in a
271 general population showed that relationships between affect and somatic symptoms are better explained
272 on a between-individual level by negative affect and on a within-individual level by positive affect [39].
273 Consequently, future studies on the relationships between affect or psychological issues (such as
274 depression, anxiety or uncertainty) and post-COVID-19 symptoms should account for within-individual
275 differences that may be obscured by between-individual findings. Moreover, for treatment, this indicates

Affect and Post-COVID-19 Symptoms in Daily Life

276 that different (affect-related) psychological approaches might be necessary and promising when dealing
277 with symptom (self-)management.

278 Results also showed between- and within-individual differences in symptom severity. Not all
279 participants experienced the same symptoms, and did not experience these symptoms at similar times.
280 Moreover, no clear temporal trajectories could be observed in patients who experienced certain
281 symptoms. For example, participants either experienced always severe or no dyspnoea, or the severity
282 fluctuated for – as of yet – undetermined reasons (S2). Aside from small influences of affect, these
283 fluctuations may be partially explained by exertion and daily activities, as previously explored for
284 physical and mental fatigue in this sample [25].

285 Overall, present symptoms seemed to mostly co-occur, as they associated positively with each
286 other over time within this sample– especially within somatic symptoms. Previously, it was shown using
287 cross-sectional measures that many post-COVID-19 patients experience multiple symptoms (e.g.
288 combinations of fatigue and pain, respiratory issues, and cognitive problems) at the same time, adding
289 to the experienced disease burden [3]. The current study adds to the understanding that symptoms might
290 influence each other’s severity. Interestingly, these associations could also be beneficial for patients, as
291 it suggests that successfully targeting one symptom (e.g. dyspnoea) for an intervention might also result
292 in a reduction in other symptoms (e.g. physical fatigue and pain). Although the present study cannot
293 provide full evidence for this, these general trends may indicate that in accordance with the Broaden-
294 and-Build framework and previous empirical findings that investigated sum score measures of
295 symptoms [e.g., 39, 40], an overall increased well-being might similarly result in an overall decrease in
296 symptom severity.

297 Taken together, our findings, especially on the role of positive affect, may serve as ground for
298 exploration of an affect-based intervention, such as a positive psychological intervention (PPI). PPI have
299 been found to be effective especially in chronic pain management and self-regulation [41, 42], and in
300 reducing distress [43]. Therefore, they seem useful for post-COVID-19 symptom management.
301 Additionally, an advantage of PPI is that they may provide participants with a sense of control over their
302 rehabilitation. Perceived control was found to be severely impacted in post-COVID-19 patients [13].
303 Moreover, the effects of PPI are quickly noticeable by participants [see e.g. 44]. To make best use of

Affect and Post-COVID-19 Symptoms in Daily Life

304 these interventions, tailoring to participants' needs might be necessary. Given the temporal association
305 between (positive) affect and symptom severity, tailored adaptive interventions that identify specific
306 times at which PPI could best take place (e.g. just-in-time adaptive interventions) seem promising.
307 Future studies should explore the best targets for these times, or whether these interventions should even
308 be time-based.

309 The strength of this study is the experience sampling methodology, which allowed for an in-
310 depth exploration of real-time assessed affect and symptom severity, increasing the reliability and
311 ecological validity [23]. Moreover, by plotting participants' individual experiences of affect and
312 symptoms over the day, a deep understanding was gained. Although this analytical strategy compensated
313 for the small sample, the sample size can be seen as a limitation. Care should be taken to generalise the
314 results. Evidence for temporal symptom patterns and stronger affect variability or instability may have
315 arisen in a larger sample. Moreover, while the number of observations included was high, an average
316 response rate of 60% is – while acceptable for ESM studies [23, 26] – rather low. Additionally, the
317 sample was mostly homogeneous and consisted of patients with a relatively long course of post-COVID-
318 19 syndrome following COVID-19 hospitalisation. Participants may have already learnt to live with
319 their illness, as well as how to deal with certain negative emotions. Consequently, more recently
320 diagnosed patients may experience more negative affect or higher symptom severity. Similarly, the
321 effects of (the number of) vaccinations have not been accounted for. These have been shown to produce
322 certain ameliorating effects on post-COVID-19 syndrome [45].

323

324 **Conclusions**

325 This study used an Experience Sampling Methodology to assess the temporal courses of and
326 relations between affect and symptoms in the post-COVID-19 patients. It provided important insights
327 in the momentary and prospective interactions between affect and post-COVID-19 symptoms. Both
328 positive and negative affect play small but important roles in the severity of fatigue, cognitive
329 dysfunction and dyspnoea and the presence of pain. Future studies should replicate and further explore

Affect and Post-COVID-19 Symptoms in Daily Life

330 these associations in large and more diverse samples, to use insights for advanced psychological
331 interventions for post-COVID-19 patients.

332

333 Acknowledgements

334 The authors thank Peter ten Klooster for his advice and support in data management and the statistical
335 analyses.

336

337 References

338 1. National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the
339 long-term effects of COVID-19 2021 [updated November 11; cited 2023 May 22]. Available from:
340 <https://www.nice.org.uk/guidance/ng188>.

341 2. Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of
342 Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and
343 Systematic Review. *J Infect Dis.* 2022;226(9):1593-607. doi: 10.1093/infdis/jiac136. PubMed PMID:
344 35429399; PubMed Central PMCID: PMCPMC9047189.

345 3. Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of
346 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following
347 Symptomatic COVID-19 in 2020 and 2021. *JAMA.* 2022;328(16):1604-15. doi:
348 10.1001/jama.2022.18931.

349 4. O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence
350 and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A
351 systematic review and meta-analysis. *EClinicalMedicine.* 2023;55:101762. Epub 20221201. doi:
352 10.1016/j.eclinm.2022.101762. PubMed PMID: 36474804; PubMed Central PMCID:
353 PMCPMC9714474.

354 5. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et
355 al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv.

Affect and Post-COVID-19 Symptoms in Daily Life

- 356 2021. Epub 2021/02/04. doi: 10.1101/2021.01.27.21250617. PubMed PMID: 33532785; PubMed
357 Central PMCID: PMC7852236 Company; the statements presented in the paper do not
358 necessarily represent the position of the company. The remaining authors have no competing interests
359 to declare.
- 360 6. Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19
361 syndrome (PCS) and health-related quality of life (HRQoL)—A systematic review and meta-analysis.
362 *J Med Virol.* 2022;94(1):253-62. doi: 10.1002/jmv.27309.
- 363 7. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and
364 symptoms, and criteria adopted for long COVID-19: A systematic review. *Int J Clin Pract.*
365 2021;75(10):e14357-e. Epub 2021/06/02. doi: 10.1111/ijcp.14357. PubMed PMID: 33977626.
- 366 8. Domingo FR, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, et al.
367 Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living
368 systematic review. *medRxiv.* 2021:2021.06.03.21258317. doi: 10.1101/2021.06.03.21258317.
- 369 9. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising
370 long COVID: a living systematic review. *BMJ Glob Health.* 2021;6(9):e005427. doi: 10.1136/bmjgh-
371 2021-005427. PubMed PMID: 34580069.
- 372 10. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms
373 after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services.
374 *BMC Health Serv Res.* 2020;20(1):1144. Epub 2020/12/22. doi: 10.1186/s12913-020-06001-y.
375 PubMed PMID: 33342437; PubMed Central PMCID: PMC7750006.
- 376 11. Buttery S, Philip KEJ, Williams P, Fallas A, West B, Cumella A, et al. Patient symptoms and
377 experience following COVID-19: Results from a UK-wide survey. *BMJ Open Respiratory Research.*
378 2021;8(1). doi: 10.1136/bmjresp-2021-001075.
- 379 12. Humphreys H, Kilby L, Kudiersky N, Copeland R. Long COVID and the role of physical
380 activity: a qualitative study. *BMJ Open.* 2021;11(3):e047632. doi: 10.1136/bmjopen-2020-047632.
- 381 13. Schaap G, Wensink M, Doggen CJM, van der Palen J, Vonkeman HE, Bode C. "It Really Is
382 an Elusive Illness"- Post-COVID-19 Illness Perceptions and Recovery Strategies: A Thematic
383 Analysis. *Int J Environ Public Health.* 2022;19(20):13003. doi: 10.3390/ijerph192013003.

Affect and Post-COVID-19 Symptoms in Daily Life

- 384 14. Fredrickson BL. The role of positive emotions in positive psychology. The broaden-and-build
385 theory of positive emotions. *Am Psychol*. 2001;56(3):218-26. doi: 10.1037//0003-066x.56.3.218.
386 PubMed PMID: 11315248; PubMed Central PMCID: PMCPMC3122271.
- 387 15. Fredrickson BL. The broaden-and-build theory of positive emotions. *Philosophical*
388 *Transactions of the Royal Society of London Series B: Biological Sciences*. 2004;359(1449):1367-77.
389 doi: 10.1098/rstb.2004.1512.
- 390 16. Frijda NH. *The emotions*. Paris, France: Editions de la Maison des Sciences de l'Homme;
391 1986. xii, 544-xii, p.
- 392 17. von Leupoldt A, Denutte Y. Affective traits, states, and breathlessness. *Curr Opin Support*
393 *Palliat Care*. 2020;14(3):182-9. doi: 10.1097/spc.0000000000000506. PubMed PMID: 01263393-
394 202009000-00006.
- 395 18. Finan PH, Garland EL. The role of positive affect in pain and its treatment. *Clin J Pain*.
396 2015;31(2):177-87. doi: 10.1097/AJP.0000000000000092.
- 397 19. Hanssen MM, Peters ML, Boselie JJ, Meulders A. Can positive affect attenuate (persistent)
398 pain? State of the art and clinical implications. *Current Rheumatology Reports*. 2017;19(12):80. doi:
399 10.1007/s11926-017-0703-3.
- 400 20. Ong AD, Thoemmes F, Ratner K, Ghezzi-Kopel K, Reid MC. Positive affect and chronic
401 pain: a preregistered systematic review and meta-analysis. *PAIN*. 2020;161(6):1140-9. doi:
402 10.1097/j.pain.0000000000001828. PubMed PMID: 00006396-202006000-00004.
- 403 21. Strebkova R. Subjective Well-Being and its Impact on Cancer-Related Fatigue in Patients
404 Undergoing Radiotherapy and Long-Term Survivors. *Acta Medica Bulgarica*. 2020;47(4):18-23. doi:
405 doi:10.2478/amb-2020-0040.
- 406 22. Toussaint LL, Vincent A, McAllister SJ, Oh TH, Hassett AL. A comparison of fibromyalgia
407 symptoms in patients with Healthy versus Depressive, Low and Reactive affect balance styles. *Scand J*
408 *Pain*. 2014;5(3):161-6. doi: 10.1016/j.sjpain.2014.05.001.
- 409 23. Myin-Germeys I, Kuppens P, editors. *The open handbook of experience sampling*
410 *methodology: A step-by-step guide to designing, conducting, and analyzing ESM studies*. 2nd ed.
411 Leuven: Center for Research on Experience Sampling and Ambulatory Methods Leuven; 2022.

Affect and Post-COVID-19 Symptoms in Daily Life

- 412 24. Aaronson NK, Muller M, Cohen PDA, Essink-Bot M-L, Fekkes M, Sanderman R, et al.
413 Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in
414 Community and Chronic Disease Populations. *J Clin Epidemiol*. 1998;51(11):1055-68. doi:
415 10.1016/S0895-4356(98)00097-3.
- 416 25. Wensink M, Schaap G, ten Klooster PM, Doggen CJM, van der Palen J, Vonkeman HE, et al.
417 Physical and mental fatigue in post-COVID syndrome and their associations over time: A small-
418 sample ESM-study to explore fatigue, quality of sleep and behaviours. *J Psychosom Res*.
419 2023;164:111084. doi: <https://doi.org/10.1016/j.jpsychores.2022.111084>.
- 420 26. Conner TS, Lehman BJ. Launching a Study in Daily Life. In: Mehl M, Conner TS, editors.
421 Handbook of Research Methods for Studying Daily Life. New York: Guilford Press; 2012. p. 88 - 107.
- 422 27. Brys ADH, Stiff F, Van Heugten CM, Bossola M, Gambaro G, Lenaert B. Unraveling Fatigue
423 in Hemodialysis Patients: Comparing Retrospective Reports to Real-Time Assessments With an
424 mHealth Experienced Sampling Method. *J Pain Symptom Manage*. 2020;60(6):1100-8.e2. doi:
425 10.1016/j.jpainsymman.2020.06.042.
- 426 28. Dietvorst E, Hiemstra M, Maciejewski D, van Roekel E, Bogt Tt, Hillegers M, et al. Grumpy
427 or depressed? Disentangling typically developing adolescent mood from prodromal depression using
428 experience sampling methods. *J Adolesc*. 2021;88:25-35. doi: 10.1016/j.adolescence.2021.01.009.
- 429 29. Jean FAM, Sibon I, Husky M, Couffinhall T, Swendsen J. Feasibility and validity of
430 Ecological Momentary Assessment in patients with acute coronary syndrome. *BMC Cardiovasc*
431 *Disord*. 2020;20(1). doi: 10.1186/s12872-020-01774-w.
- 432 30. Kratz AL, Braley TJ, Foxen-Craft E, Scott E, Murphy JF, Murphy SL. How Do Pain, Fatigue,
433 Depressive, and Cognitive Symptoms Relate to Well-Being and Social and Physical Functioning in the
434 Daily Lives of Individuals With Multiple Sclerosis? *Arch Phys Med Rehabil*. 2017;98(11):2160-6.
435 doi: 10.1016/j.apmr.2017.07.004.
- 436 31. Lenaert B, Neijmeijer M, van Kampen N, van Heugten C, Ponds R. Poststroke Fatigue and
437 Daily Activity Patterns During Outpatient Rehabilitation: An Experience Sampling Method Study.
438 *Arch Phys Med Rehabil*. 2020;101(6):1001-8. doi: 10.1016/j.apmr.2019.12.014. PubMed PMID:
439 WOS:000543030600008.

Affect and Post-COVID-19 Symptoms in Daily Life

- 440 32. Maes IHL, Delespaul PAEG, Peters ML, White MP, van Horn Y, Schruers K, et al. Measuring
441 Health-Related Quality of Life by Experiences: The Experience Sampling Method. *Value Health*.
442 2015;18(1):44-51. doi: 10.1016/j.jval.2014.10.003.
- 443 33. Romano KA, Heron KE, Smith KE, Crosby RD, Engel SG, Wonderlich SA, et al. Somatic
444 symptoms and binge eating in women's daily lives. *J Psychosom Res*. 2020;135. doi:
445 10.1016/j.jpsychores.2020.110161.
- 446 34. Worm-Smeitink M, Monden R, Groen RN, van Gils A, Bekhuis E, Rosmalen J, et al. Towards
447 personalized assessment of fatigue perpetuating factors in patients with chronic fatigue syndrome
448 using ecological momentary assessment: A pilot study. *J Psychosom Res*. 2021;140. doi:
449 10.1016/j.jpsychores.2020.110296.
- 450 35. Posit Team. RStudio: Integrated Development Environment for R: Posit Software, PBC; 2023.
451 Available from: <https://posit.co/>.
- 452 36. Cohen J. *Statistical Power Analysis for the Behavioural Sciences*: Academic Press, New York;
453 1988.
- 454 37. Zautra AJ, Fasman R, Parish BP, Davis MC. Daily fatigue in women with osteoarthritis,
455 rheumatoid arthritis, and fibromyalgia. *Pain*. 2007;128(1):128-35. doi: 10.1016/j.pain.2006.09.004.
- 456 38. Van Den Houte M, Bogaerts K, Van Diest I, De Bie J, Persoons P, Van Oudenhove L, et al.
457 Inducing Somatic Symptoms in Functional Syndrome Patients: Effects of Manipulating State Negative
458 Affect. *Psychosom Med*. 2017;79(9):1000-7. doi: 10.1097/psy.0000000000000527. PubMed PMID:
459 00006842-201711000-00007.
- 460 39. Schenk HM, Bos EH, Slaets JPI, de Jonge P, Rosmalen JGM. Differential association between
461 affect and somatic symptoms at the between- and within-individual level. *Br J Health Psychol*.
462 2017;22(2):270-80. doi: 10.1111/bjhp.12229.
- 463 40. Clark LA, Watson D. Mood and the mundane: relations between daily life events and self-
464 reported mood. *J Pers Soc Psychol*. 1988;54(2):296-308. doi: 10.1037//0022-3514.54.2.296. PubMed
465 PMID: 3346815.

Affect and Post-COVID-19 Symptoms in Daily Life

- 466 41. Braunwalder C, Müller R, Glisic M, Fekete C. Are Positive Psychology Interventions
467 Efficacious in Chronic Pain Treatment? A Systematic Review and Meta-Analysis of Randomized
468 Controlled Trials. *Pain Med.* 2021;23(1):122-36. doi: 10.1093/pm/pnab247.
- 469 42. Iddon JE, Dickson JM, Unwin J. Positive Psychological Interventions and Chronic Non-
470 Cancer Pain: A Systematic Review of the Literature. *Int J Appl Posit Psychol.* 2016;1(1):133-57. doi:
471 10.1007/s41042-016-0003-6.
- 472 43. Chakhssi F, Kraiss JT, Sommers-Spijkerman M, Bohlmeijer ET. The effect of positive
473 psychology interventions on well-being and distress in clinical samples with psychiatric or somatic
474 disorders: a systematic review and meta-analysis. *BMC Psychiatry.* 2018;18(1):211. Epub 20180627.
475 doi: 10.1186/s12888-018-1739-2. PubMed PMID: 29945603; PubMed Central PMCID:
476 PMC6020379.
- 477 44. Geschwind N, Arntz A, Bannink F, Peeters F. Positive cognitive behavior therapy in the
478 treatment of depression: A randomized order within-subject comparison with traditional cognitive
479 behavior therapy. *Behav Res Ther.* 2019;116:119-30. Epub 20190309. doi:
480 10.1016/j.brat.2019.03.005. PubMed PMID: 30897464.
- 481 45. Tofarides AG, Christaki E, Milionis H, Nikolopoulos GK. Effect of Vaccination against
482 SARS-CoV-2 on Long COVID-19: A Narrative Review. *Life (Basel).* 2022;12(12). Epub 20221208.
483 doi: 10.3390/life12122057. PubMed PMID: 36556422; PubMed Central PMCID: PMC6020379.
484

485 **Supporting information**

486 **S1. Morning and momentary questionnaires**

487 **S2. Visualisations of courses of symptoms with concurrent affect**

488 **S3. Visualisations of courses of symptoms with time-lagged affect**

489 **S4. Visualisations of courses of affect and of specified pains**





Fig 1



Affect at Corresponding Time ● Predominantly positive ▲ Predominantly negative ■ Neither positive nor negative